Mounjaro is a dual GIP and GLP-1 receptor agonist licensed in the UK for type 2 diabetes mellitus treatment The mechanism behind taste alterations remains unclear but may relate to effects on gastric emptying, blood glucose fluctuations, or gastrointestinal symptoms Taste changes are generally temporary and tend to resolve as the body adjusts to treatment Contact your GP if taste disturbances persist beyond 46 weeks, significantly affect nutrition, or are accompanied by concerning symptoms such as severe abdominal pain or oral lesions Table of Contents Why Does Mounjaro Cause a Sweet Taste in Your Mouth
D thuc gip bn kim sot cn i mt cch d dng hn, hiu qu gim cn lu di vn ph thuc mt thit vo thi quen dinh dng v vn ng
The absolute abundance of these pathways was positively correlated with the area under the IPGTT curve and insulin level ( Figure 5 )
G., Blissmer, B
The SELECT cardiovascular outcomes trial (n=17,604) demonstrated a 20% relative risk reduction in major adverse cardiovascular events in adults with obesity and established cardiovascular disease
The ADA 2026 Standards of Care now recommend GLP-1 receptor agonists with demonstrated cardiovascular benefit for patients with type 2 diabetes and established ASCVD, multiple cardiovascular risk factors, or chronic kidney disease, and note that combination with SGLT2 inhibitors may provide additive benefit
